MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/140/0.1/20.12.24 | Market Closed - Bid/Ask 12:05:13 27/06/2024 am IST | ||
| 0.183 EUR | 0.00% |
|
| Current month | +83.00% | ||
| 1 month | +238.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 0.183 | 0.00% |
| 25/24/25 | 0.183 | +16.56% |
| 24/24/24 | 0.157 | +0.64% |
| 21/24/21 | 0.156 | -1.27% |
| 20/24/20 | 0.158 | +3.27% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 12:05 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB8GNB |
| ISIN | DE000MB8GNB3 |
| Date issued | 07/07/2023 |
| Strike | 140 $ |
| Maturity | 20/12/2024 (177 Days) |
| Parity | 10 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.31 € |
|---|---|
| Lowest since issue | 0.044 € |
| Spread | 0.01 € |
| Spread % | 5.18% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
91.08
USD
Average target price
96.05
USD
Spread / Average Target
+5.46%
- Stock Market
- Warrants
- Warrant
